Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04837196
Title Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Astellas Pharma Global Development, Inc.
Indications

melanoma

Advanced Solid Tumor

ovarian cancer

colorectal cancer

Therapies

ASP7517 + Pembrolizumab

ASP7517

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST